open, non comparative, prospectic, phase IV clinical study to evaluate the activity and tolerance of Cinacalcet-HCl (drug name Mimpara) in patients affected by MEN1-associated primary hyperparathyroidism

Femme et Homme

| Pays :
| Organes :
| Spécialités :

Extrait

To study the activities of Cinacalcet- HCl administered to patients with MEN1-associated primary hyperparathyroidism (plasma PTH> 7.6 pmol / ml or 70 pg / ml and total serum calcium> 10.3 mg / dl or 2.57 mmol / l) at doses of 30 mg 1-2 times / day (starting with 30 mg per day, increasing the dose to 30 mg 2 times day, up to a maximum of 40-50 mg 2 times per day, if at the next inspection calcemia was still greater than 10.3 mg / dl or 2.57 mmol / l), considering: a) reduction or normalization of the levels of PTH and calcium; b) reducing or maintaining the size of parathyroid tissue affected

Critère d'inclusion

Primary hyperparathyroidism in patients with MEN1

Liens

euctr
ictrp

Kusajili – Centralise les essais cliniques mondiaux

open, non comparative, prospectic, phase IV clinical study to evaluate the activity and tolerance of Cinacalcet-HCl (drug name Mimpara) in patients affected by MEN1-associated primary hyperparathyroid...